News & Events about Novocure Limited.
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocures Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilities for...
NovoCure Limited (NASDAQ:NVCR Get Rating) has earned an average recommendation of Hold from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating ...
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and...
NovoCure (NASDAQ:NVCR Get Rating) had its price objective raised by research analysts at JPMorgan Chase & Co. from $86.00 to $99.00 in a report released on Friday, Benzinga reports. The brokerage presently has a neutral rating on the medical equipment providers stock. JPMorgan Chase & Co.s price ...